6:31 PM
 | 
Jun 02, 2008
 |  BC Extra  |  Clinical News

Avant up on CDX-110 results

Avant gained $3.97 (28%) to $17.98 after it and partner Pfizer (NYSE:PFE) reported data from a pair of open-label, Phase II trials of CDX-110 to treat glioblastoma multiforme (GBM). Preliminary data from the ACT II trial of...

Read the full 178 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >